Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35837734)
Watch
English
A tale of two receptors: insulin and insulin-like growth factor signaling in cancer
scientific article published on 10 October 2014
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
title
A tale of two receptors: insulin and insulin-like growth factor signaling in cancer
(English)
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
author
Douglas Yee
object named as
Douglas Yee
series ordinal
1
0 references
language of work or name
English
0 references
publication date
10 October 2014
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
published in
Clinical Cancer Research
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
volume
21
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
issue
4
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
page(s)
667-669
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
cites work
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Insulin-like growth factor receptor inhibitors: baby or the bathwater?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Biological effects of growth hormone on carbohydrate and lipid metabolism.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
11 July 2018
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
24 September 2018
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4498265
retrieved
24 September 2018
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25303978
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1158/1078-0432.CCR-14-2056
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
PMCID
4498265
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
PubMed ID
25303978
1 reference
stated in
Europe PubMed Central
PMCID
4498265
retrieved
10 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit